CXXC4增强上皮性卵巢癌细胞对化疗药物的敏感性

doi:10.6040/j.issn.1671-7554.0.2015.359

摘要/Abstract

摘要： 目的探讨CXXC4对卵巢癌细胞的增殖及药物敏感性的影响。方法采用Western blotting和Real-time PCR分别从蛋白水平和mRNA水平检测正常卵巢上皮细胞和卵巢癌细胞中的CXXC4表达,脂质体法将重组质粒pcDNA3-CXXC4和siRNA-CXXC4分别转染人卵巢癌细胞SKOV3、Caov3和正常卵巢上皮细胞IOSE80,CCK8法分析CXXC4对细胞增殖及药物敏感性的影响。结果与正常卵巢上皮细胞相比,卵巢癌细胞中CXXC4低表达,外源性CXXC4过表达抑制卵巢癌细胞SKOV3、Caov3的增殖能力,以及增强肿瘤细胞对化疗药物的敏感性;降低CXXC4的表达能促进正常卵巢上皮细胞的增殖能力,促进细胞对化疗药物的耐受。结论 CXXC4的过表达抑制卵巢癌细胞的增殖能力,且增强肿瘤细胞对化疗药物的敏感性,提示其可能作为一个潜在的卵巢癌疗效预测标记物以及化疗增敏的分子靶点。

关键词: CXXC4, 卵巢癌, 耐药, 增殖

Abstract: Objective To explore the effect of CXXC4 on the proliferation and sensitivity to chemotherapy drugs in ovarian carcinoma cells. Methods Protein and mRNA levels of CXXC4 were detected in nomal ovarian epithelial cells and ovarian carcinoma cells by Western blotting and Real-time PCR, respectively. The recombinant plasmid pcDNA3-CXXC4 and siRNA-CXXC4 were transfected into SKOV3, Caov3 cells and IOSE80 cells via Lipo2000. CCK8 assay was used to evaluate the effect of CXXC4 on the proliferation and sensitivity to chemotherapy drugs. Results Compared with the normal ovarian epithelial cells, CXXC4 expression was lower in ovarian carcinoma cells. Overexpression of CXXC4 inhibited the proliferation capacity and increased the sensitivity to chemotherapy drugs in SKOV3 and Caov3 cells. Decreased CXXC4 expression could promote the proliferation capacity and the chemo-resistance to chemotherapy drugs of normal ovarian epithelial cells. Conclusion Overexpression of CXXC4 could inhibit the proliferation capacity and increase the sensitivity to chemotherapy drugs in ovarian carcinoma cells, suggesting it would be a potential biomarker to predict the efficacy or a molecular target to enhance the efficacy to chemotherapy in ovarian carcinoma cells.

Key words: Ovarian cancer, Chemo-resistance, CXXC4, Proliferation

中图分类号:

R737.31

赵云霞,宋静,张灿灿,林雪艳,尉蔚,田永杰. CXXC4增强上皮性卵巢癌细胞对化疗药物的敏感性[J]. 山东大学学报（医学版）, 2016, 54(3): 24-29.

ZHAO Yunxia, SONG Jing, ZHANG Cancan, LIN Xueyan, WEI Wei, TIAN Yongjie. CXXC4 promotes sensitivity to chemotherapy drugs in epithelial ovarian cancer cells[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 24-29.

参考文献

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤, 2014, 23(1):1-10. CHEN Wanqing, ZHANG Siwei, ZENG Hongmei, et al. Report of cancer incidence and mortality in China, 2010[J]. China Cancer, 2014, 23(1):1-10.
[3] Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011, 61(3):183-203.
[4] Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer[J]. N Engl J Med, 2010, 363(10):943-953.
[5] Cannistra SA. Cancer of the ovary[J]. N Engl J Med, 2004, 351(24):2519-2529.
[6] Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24(Suppl 6):vi24-vi32.
[7] Jemal A, Siegel R, Xu J, et al. Cancer statistics[J]. CA Cancer J Clin, 2010, 60(5):277-300.
[8] Hino S, Kishida S, Michiue T, et al. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein[J]. Mol Cell Biol, 2001, 21(1):330-342.
[9] Michiue T, Fukui A, Yukita A, et al. XIdax, an inhibitor of the canonical Wnt pathway, is required for anterior neural structure formation in Xenopus [J]. Dev Dyn, 2004, 230(1):79-90.
[10] Kojima T, Shimazui T, Hinotsu S, et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling [J]. Oncogene, 2009, 28(2):297-305.
[11] Colombo PE, Fabbro M, Theillet C, et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer [J]. Crit Rev Oncol/Hematol, 2014, 89(2):207-216.
[12] Thigpen T. A rational approach to the management of recurrent or persistent ovarian carcinoma [J]. Clin Obstet Gynecol, 2012, 55(1):114-130.
[13] Abada P, Howell SB. Regulation of Cisplatin cytotoxicity by cu influx transporters [J]. Metal Based Drugs, 2010:317581. doi:10.1155/2010/317581.
[14] Helleman J, van Staveren IL, Dinjens WN, et al. Mismatch repair and treatment resistance in ovarian cancer [J]. BMC Cancer, 2006, 6:201.
[15] Surowiak P, Materna V, Kaplenko I, et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients[J]. Virchows Arch, 2005, 447(3):626-633.
[16] Kobayashi Y, Seino K, Hosonuma S, et al. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin[J]. Gynecol Oncol, 2011, 121(2):390-394.
[17] Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant[J]. Br J Cancer, 2010, 102(8):1276-1283.
[18] Wang QE, Han C, Milum K, et al. Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment[J]. Mutat Res, 2011, 708(1-2):59-68.
[19] Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance[J]. Cell Cycle, 2009, 8(1):158-166.
[20] Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells[J]. Stem Cells, 2009, 27(9):2059-2068.
[21] Lu H, Sun J, Wang F, et al. Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4[J]. Cell Death Dis, 2013, 4:e776. doi:10.1038/cddis.2013.293.
[22] Lu H, Jin W, Sun J, et al. New tumor suppressor CXXC finger protein 4 inactivates mitogen activated protein kinase signaling[J]. FEBS Lett, 2014, 588(18):3322-3326.
[23] Arend RC, Londono-Joshi AI, Straughn JM, et al. The Wnt/beta-catenin pathway in ovarian cancer:a review [J]. Gynecol Oncol, 2013, 131(3):772-779.
[24] Fan HY, Liu Z, Mullany LK, et al. Consequences of RAS and MAPK activation in the ovary:the good, the bad and the ugly [J]. Mol Cell Endocrinol, 2012, 356(1-2):74-79.
[25] Grendys EC, Wang D, Tian C, et al. Overview of a chemoresponse assay in ovarian cancer [J]. Clin Transl Oncol, 2014, 16(9):761-769.
[26] Han Y, Huang H, Xiao Z, et al. Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer [J]. PloS One, 2012, 7(12):e52745. doi:10.1371/journal.pone.0052745.

相关文章 15

[1]	王晓磊张海涛张辉郭成浩. 舒血宁注射液对高碘致培养血管内皮细胞损伤的保护作用[J]. 山东大学学报(医学版), 2209, 47(6): 38-.
[2]	葛丽娟金瑞峰王纪文许新升李癊. 多药耐药基因1 C1236T多态性与癫痫患者对药物反应性的相关性[J]. 山东大学学报(医学版), 2209, 47(6): 99-102.
[3]	李涵,付婷婷,张磊,延冰,孙涛,郭峰,尹晓. 过氧化物酶增殖物激活受体γ激动剂对24例肥胖症患者米色脂肪细胞分化的影响[J]. 山东大学学报 (医学版), 2020, 1(9): 8-13.
[4]	孙薏丰,高玉,梁永媛,高杨. CPLX2在30例肝癌组织的表达及其对体外细胞增殖与侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(9): 34-39.
[5]	张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[6]	付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24-31.
[7]	马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32-37.
[8]	李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38-46.
[9]	董伟,邢乃栋,吕家驹,刘帅,孙亮,曹庆伟,董宇昊,刘钊,丁森泰. 靶向抑制有丝分裂驱动蛋白治疗多西紫杉醇耐药前列腺癌的体外疗效[J]. 山东大学学报（医学版）, 2017, 55(9): 23-30.
[10]	王凯民,谭娟娟,严志强,李志强. Sirtuin在低氧诱导人脐带间充质干细胞增殖中的作用[J]. 山东大学学报（医学版）, 2017, 55(7): 23-30.
[11]	李安, 陈丰哲,王正,孟祥珠,许楠楠,马立宪. 西他沙星、头孢哌酮/舒巴坦和多黏菌素E单药及联合用药对泛耐药鲍曼不动杆菌的抗菌活性[J]. 山东大学学报（医学版）, 2017, 55(4): 82-85.
[12]	孟伟,吴大玮,单悌超,张帆,郭海鹏,刘宇,丁士芳,翟茜. 替加环素治疗重症患者呼吸机相关性肺炎[J]. 山东大学学报（医学版）, 2017, 55(4): 71-75.
[13]	史培堃,曾贝妮,吴伟芳,胡晓燕,马天加,周亚滨. Keap1在肾细胞癌中的表达及其作用[J]. 山东大学学报（医学版）, 2017, 55(3): 94-99.
[14]	孙泽雨,陈颖,林家香,刘娟,赵蔚明. 磷脂酰肌醇-4-磷酸酶II型对宫颈癌细胞增殖及凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(11): 1-6.
[15]	王甜甜,陈洁. EFEMP2在子宫内膜癌组织及细胞中的表达及其临床意义[J]. 山东大学学报（医学版）, 2017, 55(10): 52-58.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed